Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors

NCT03550508 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastases

Interventions

BIOLOGICAL: Anti-RANKL Monoclonal Antibody

Sponsor

Shanghai JMT-Bio Inc.

Collaborators

[object Object]
[object Object]
[object Object]